Exploring Three High Growth Tech Stocks in the United States

In the last week, the United States market has been flat, yet it has experienced a remarkable 31% increase over the past year with earnings forecasted to grow by 15% annually. In this environment, identifying high growth tech stocks involves looking for companies that can sustain robust growth and innovation in line with these promising market conditions.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
Super Micro Computer	20.63%	25.42%	★★★★★★
Sarepta Therapeutics	23.80%	44.01%	★★★★★★
TG Therapeutics	34.66%	56.48%	★★★★★★
Invivyd	47.87%	67.72%	★★★★★★
Amicus Therapeutics	20.26%	62.89%	★★★★★★
Alkami Technology	21.90%	98.60%	★★★★★★
Alnylam Pharmaceuticals	22.41%	70.53%	★★★★★★
Travere Therapeutics	31.20%	72.26%	★★★★★★
Seagen	22.57%	71.80%	★★★★★★
ImmunoGen	26.00%	45.85%	★★★★★★

Click here to see the full list of 241 stocks from our US High Growth Tech and AI Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Vertex (NasdaqGM:VERX)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Vertex, Inc. offers enterprise tax technology solutions for the retail trade, wholesale trade, and manufacturing industries both in the United States and internationally, with a market cap of approximately $6.57 billion.

Operations: Vertex, Inc. generates revenue primarily from its software and programming segment, amounting to $617.83 million. The company specializes in providing tax technology solutions across various industries globally.

Vertex, Inc. has demonstrated a robust trajectory in the tech sector, notably with a 12.9% forecasted annual revenue growth outpacing the US market's 8.8%. This growth is underpinned by significant advancements in R&D, with expenses strategically allocated to foster innovations like the integration of Vertex for Salesforce Revenue Cloud, enhancing tax compliance and operational efficiency for businesses. Furthermore, Vertex's earnings are expected to surge by 36.8% annually, reflecting potent future prospects despite recent challenges such as a substantial one-off loss of $7.7 million affecting financial outcomes. The firm's strategic focus on expanding its cloud-based solutions is evident from its latest guidance update, projecting cloud revenue growth at an impressive rate of 28%, positioning it well within the competitive tech landscape.

• Click here and access our complete health analysis report to understand the dynamics of Vertex.

• Examine Vertex's past performance report to understand how it has performed in the past.

Day One Biopharmaceuticals (NasdaqGS:DAWN)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for patients with genomically defined cancers, with a market cap of $1.49 billion.

Operations: Day One Biopharmaceuticals focuses on developing targeted cancer therapies, with a market capitalization of approximately $1.49 billion. The company is in the clinical stage and does not currently report revenue streams.

Day One Biopharmaceuticals has pivoted from a substantial net loss to reporting a net income of $37.04 million in Q3 2024, signaling potential recovery and growth. This turnaround is underscored by an impressive expected annual revenue growth rate of 39.4%, significantly outpacing the broader US market's 8.8%. Moreover, the company's commitment to innovation is evident from its R&D investments, which are crucial as it gears up for profitability with earnings projected to surge by 67.3% annually. These strategic moves could position Day One well within the competitive biotech landscape, despite current unprofitability and past shareholder dilution.

• Take a closer look at Day One Biopharmaceuticals' potential here in our health report.

• Explore historical data to track Day One Biopharmaceuticals' performance over time in our Past section.

DoubleVerify Holdings (NYSE:DV)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: DoubleVerify Holdings, Inc. offers a software platform focused on digital media measurement and data analytics both in the United States and globally, with a market capitalization of approximately $2.98 billion.

Operations: DoubleVerify Holdings generates revenue primarily from its data processing services, amounting to $612.88 million. The company's business centers around providing digital media measurement and analytics solutions on a global scale.

DoubleVerify Holdings (DV) is demonstrating robust growth with revenue and earnings forecasted to rise by 14% and 21.1% per year, respectively, outpacing the broader US market. This growth trajectory is supported by strategic integrations with platforms like Snap and Spotify, enhancing DV's media quality measurement services. These partnerships leverage DV’s AI-driven technology to ensure brand safety, boosting advertiser confidence and potentially increasing market share in the digital advertising space. Moreover, DV's recent expansion into LinkedIn's premium video inventory underscores its commitment to broadening its service capabilities, which could further solidify its position in a competitive industry.

• Delve into the full analysis health report here for a deeper understanding of DoubleVerify Holdings.

• Assess DoubleVerify Holdings' past performance with our detailed historical performance reports.

Taking Advantage

• Get an in-depth perspective on all 241 US High Growth Tech and AI Stocks by using our screener here.
• Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
• Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com